SOURCE: NASDAQ

August 18, 2005 12:00 ET

Panacos Pharmaceuticals [PANC] Chairman and CEO to Ring The NASDAQ Stock Market Closing Bell

Company Celebrates Name Change

-- (MARKET WIRE) -- August 18, 2005 --


What:

Samuel "Skip" Ackerman, Chairman and CEO of Panacos Pharmaceuticals (NASDAQ: PANC), will preside over the closing bell. V.I. Technologies, Inc. recently merged with Panacos Pharmaceuticals and began trading under the new name Panacos Pharmaceuticals.

Where:

NASDAQ MarketSite -- 4 Times Square -- 43rd & Broadway -- Broadcast Studio

When:

Friday, August 19th, 2005, at 4:00 p.m. EDT

Feed Information:

The closing bell is available from 3:50 p.m. to 4:05 p.m. on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Stephanie Lowenthal at (646) 441-5220.

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Panacos Pharmaceuticals:

Panacos is developing the next generation of antiviral products. The Company is engaged in the discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Panacos proprietary discovery technologies and lead therapeutic candidate PA-457 focus on novel targets in the virus life cycle, including virus fusion and virus maturation. PA-457 is the first in a new class of HIV drugs called Maturation Inhibitors discovered by the Company, with broad activity against HIV, including strains resistant to currently approved drugs, the leading cause of HIV treatment failure. It is currently in Phase 2 clinical testing for treatment of HIV infection. For more information on Panacos, please visit our web site at: http://www.panacos.com.

Contact Information

  • Contacts:
    Michele Fox/Luciana Canestraro
    Schwartz Communications
    Email Contact

    NASDAQ MarketSite:
    Stephanie Lowenthal
    646.441.5220